Portfolio company
Amphista Therapeutics
United Kingdom
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
3 investors
Sectors
About
This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Nurix Therapeutics
This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.
Ambagon Therapeutics
The company develops small-molecule stabilisers to modulate protein interactions for the treatment of cancer and other serious diseases.
Kymera Therapeutics
This biotechnology company develops small molecule medicines that degrade disease-causing proteins for patients with cancer and immune-inflammatory diseases.
Enodia
This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.
Plexium
This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.
UPPTHERA
The company develops targeted protein degradation therapies for patients with cancer and rare diseases and provides platform technologies to pharmaceutical and biotechnology companies.